These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 2759355)
21. Industry perspective for biotech products. Möritz A Dev Biol (Basel); 2004; 118():37-44. PubMed ID: 15645671 [TBL] [Abstract][Full Text] [Related]
22. Human and veterinary drugs: good manufacturing practices and proposed exemptions for certain OTC products. Fed Regist; 1978 Sep; 43(190 Pt 2):45013-89. PubMed ID: 10316700 [No Abstract] [Full Text] [Related]
23. Symposium on Continuous Cell Lines as Substrates for Biologicals. Arlington, Virginia, USA (Washington, D.C.), May 26-29, 1988. Proceedings. Dev Biol Stand; 1989; 70():1-304. PubMed ID: 2759343 [No Abstract] [Full Text] [Related]
24. Definition of a well-characterized biotechnology product. Zoon K; Garnick R Dev Biol Stand; 1998; 96():191-7. PubMed ID: 9890531 [No Abstract] [Full Text] [Related]
25. The FDA's accelerated approval process: does the pharmaceutical industry have adequate incentives for self-regulation? Orlando VI Am J Law Med; 1999; 25(4):543-68. PubMed ID: 10629734 [No Abstract] [Full Text] [Related]
26. Clinical quality assurance in the pharmaceutical industry. Donahue JJ Cancer Treat Rep; 1985 Oct; 69(10):1195-7. PubMed ID: 4042098 [No Abstract] [Full Text] [Related]
27. Deterring the importation of counterfeit pharmaceutical products. Stearn DW Food Drug Law J; 2004; 59(4):537-61. PubMed ID: 15875351 [No Abstract] [Full Text] [Related]
28. Draft guidance for industry on developing medical imaging drugs and biologics; availability--FDA. Availability of guidance. Fed Regist; 1998 Oct; 63(198):55067-9. PubMed ID: 10185833 [TBL] [Abstract][Full Text] [Related]
29. Securing the US pharmaceutical supply. Somberg JC Am J Ther; 2008; 15(3):197. PubMed ID: 18496255 [No Abstract] [Full Text] [Related]
30. Acceptability of cell substrates for production of biologicals. Report of a WHO Study Group on Biologicals. World Health Organ Tech Rep Ser; 1987; 747():1-29. PubMed ID: 3107222 [No Abstract] [Full Text] [Related]
31. Toward more effective drug regulation. Schmidt AM FDA Consum; 1975 Dec-1976 Jan; 9(10):27-9. PubMed ID: 10316532 [No Abstract] [Full Text] [Related]
32. Well-characterized biotechnology products: evolving to meet the needs of the 21st century. Zoon KC Dev Biol Stand; 1998; 96():3-8. PubMed ID: 9890510 [No Abstract] [Full Text] [Related]
33. Medicare program; manufacturer submission of manufacturer's average sales price (ASP) data for Medicare Part B drugs and biologicals. Final rule. Centers for Medicare & Medicaid Services (CMS), HHS Fed Regist; 2004 Sep; 69(179):55763-5. PubMed ID: 15372731 [TBL] [Abstract][Full Text] [Related]
34. Current good manufacturing practices for PET drug products in the United States. Swanson D; Graham M; Heinonen TM; Libby P; Mills GQ J Nucl Med; 2009 Aug; 50(8):26N-8N. PubMed ID: 19652213 [No Abstract] [Full Text] [Related]
35. Commentary: Epidemiology and the pharmaceutical industry: an inside perspective. Haas J Int J Epidemiol; 2008 Feb; 37(1):53-5; discussion 65-8. PubMed ID: 18184672 [No Abstract] [Full Text] [Related]
36. Medicare program; manufacturer submission of manufacturer's average sales price (ASP) data for Medicare Part B drugs and biologicals. Interim final rule with comment period. Centers for Medicare & Medicaid Services (CMS), HHS Fed Regist; 2004 Apr; 69(66):17935-41. PubMed ID: 15068020 [TBL] [Abstract][Full Text] [Related]